Section Arrow
Quote
VTVT.NASDAQ
- vTv Therapeutics
Quotes are at least 15-min delayed:2026/05/27 08:03 EDT
Pre Market
Last
 33
-0.16 (-0.48%)
Bid
29.91
Ask
37.4
High 34.01 
Low 33 
Volume 27 
Regular Hours (Closed)
Last
 33.16
-1.245 (-3.62%)
Day High 
37.4 
Prev. Close
34.405 
1-M High
38.43 
Volume 
58.21K 
Bid
29.91
Ask
37.4
Day Low
33.15 
Open
34.55 
1-M Low
28.75 
Market Cap 
135.51M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 34.68 
20-SMA 33.06 
50-SMA 35.72 
52-W High 44 
52-W Low 14 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.78/-2.99
Enterprise Value
135.51M
Balance Sheet
Book Value Per Share
22.84
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
0.00
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
OTLKOutlook Therapeutics0.4002+0.0903+29.14%-- 
Pre Market 0.3991 -0.0011 -0.27%
SNGXSoligenix Inc.0.513+0.1229+31.50%-- 
Pre Market 0.9999 +0.4869 +94.91%
PHGEBiomX Inc.1.62+0.8035+98.41%-- 
Pre Market 1.325 -0.295 -18.21%
RXRXRecursion Pharmaceuticals2.97-0.04-1.33%-- 
Pre Market 2.965 -0.005 -0.17%
ARTLArtelo Biosciences Inc1.71+0.52+43.70%-- 
Pre Market 1.26 -0.45 -26.32%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.